Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder

Abstract

In self-identified white patients with major depressive disorder (N=126) treated with open-label duloxetine (60-120. mg/d), a significant association of (P=0.020) of a composite risk score (based on SLC6A2 rs5569 [G1287A] AA, HTR1A rs6295 [C(-1019)G] GG, and COMT rs174697 AA/AG) with 17-item Hamilton Depression Rating Scale total score change from baseline to 12 weeks was observed. © 2012 Elsevier Ireland Ltd.